Trials / Recruiting
RecruitingNCT07204457
Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old
Multicenter, Randomized, Subject/Evaluator Blind, Active Control, Phase II/III Clinical Trial to Assess Immunogenicity and Safety of EG-MCV4 Meningococcal (Groups A, C, W-135, and Y) Conjugated Vaccines
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 1,123 (estimated)
- Sponsor
- EyeGene Inc. · Academic / Other
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Phase 2/3 study to evaluate immunogenicity and safety in healthy adult participants following a single dose administration of Meningococcal (groups A, C, W-135, and Y) conjugate vaccine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | EG-MCV4 | single intramuscular dose on Day 0 |
| BIOLOGICAL | Menveo | single intramuscular dose on Day 0 |
Timeline
- Start date
- 2025-10-15
- Primary completion
- 2026-09-01
- Completion
- 2027-06-01
- First posted
- 2025-10-02
- Last updated
- 2025-12-01
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT07204457. Inclusion in this directory is not an endorsement.